Mostrar el registro sencillo del ítem

dc.contributor.authorVillena-Salinas, Javier
dc.contributor.authorOrtega-Lozano, Simeón José
dc.contributor.authorAmrani-Raissouni, Tomader
dc.contributor.authorAgüera Morales, Eduardo
dc.contributor.authorCaballero-Villarraso, Javier
dc.date.accessioned2023-06-01T12:07:04Z
dc.date.available2023-06-01T12:07:04Z
dc.date.issued2023
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/10396/25449
dc.description.abstractBackground: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder that has no curative treatment. Diagnosis is based on a set of criteria established by Gilman (1998 and 2008) and recently updated by Wenning (2022). We aim to determine the effectiveness of [123I]Ioflupane SPECT in MSA, especially at the initial clinical suspicion. Methods: A cross-sectional study of patients at the initial clinical suspicion of MSA, referred for [123I]Ioflupane SPECT. Results: Overall, 139 patients (68 men, 71 women) were included, 104 being MSA-probable and 35 MSA-possible. MRI was normal in 89.2%, while SPECT was positive in 78.45%. SPECT showed high sensitivity (82.46%) and positive predictive value (86.24), reaching maximum sensitivity in MSA-P (97.26%). Significant differences were found when relating both SPECT assessments in the healthy–sick and inconclusive–sick groups. We also found an association when relating SPECT to the subtype (MSA-C or MSA-P), as well as to the presence of parkinsonian symptoms. Lateralization of striatal involvement was detected (left side). Conclusions: [123I]Ioflupane SPECT is a useful and reliable tool for diagnosing MSA, with good effectiveness and accuracy. Qualitative assessment shows a clear superiority when distinguishing between the healthy–sick categories, as well as between the parkinsonian (MSA-P) and cerebellar (MSA-C) subtypes at initial clinical suspicion.en
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.sourceJ. Clin. Med., 12(10), 3478 (2023)es_ES
dc.subjectApplications of Biomedical Technologyen
dc.subjectMolecular Biological Approachen
dc.subjectBrain Diseasesen
dc.titleDiagnostic effectiveness of [123I] Ioflupane single photon emission computed tomography (SPECT) in multiple system atrophyen
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.3390/jcm12103478es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem